Clinical value and potential association of Rab1A and FoxM1 aberrant expression in colorectal cancer

Xu, Menglin; Shao, Xinyu; Li, Haoran; Zhang, Zhengrong; Zhou, Chunli; Cheng, Zhengwu

doi:10.1038/s41598-020-77182-z

Cited by 4 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study has reported that Rab1A overexpression caused a poor prognosis in CRC 9 , 30 , 31 , GC 32 , and intrahepatic cholangiocarcinoma 19 . The Rab1A positive group had a worse prognosis than the negative group in GC patients.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Prognosis value and positive association of Rab1A/IL4Rα aberrant expression in gastric cancer

Cheng

Jiang

et al. 2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

Gastric cancer (GC) is the most common gastrointestinal cancer and the leading cause of worldwide cancer-associated mortality. Several GC patients are diagnosed at the advanced stage with an unsatisfactory 5-year survival rate. Rab1A was significantly associated with IL4Rα expression in non-small cell lung cancer. However, their potential correlation in expression and prognosis remains largely unknown in GC. In this study, Rab1A/IL-4Rα was significantly increased in GC than in para-cancerous tissues, and Rab1A/IL-4Rα overexpression caused poor prognosis among GC patients. Rab1A expression was significantly correlated with IL-4Rα expression in GC tissues, as determined by IHC analysis. In addition, the mRNA expression of Rab1A was closely linked with the IL-4Rα mRNA expression in GC tissue expressed by qPCR. Furthermore, the Kaplan–Meier analysis demonstrated that the group with negative Rab1A and IL-4Rα expression had longer 5-year survival rates than the other group. Besides, the group with positive Rab1A and IL-4Rα expression had a worse prognosis than the other group. Finally, nomograms revealed the overall 3 and 5-year survival determined crucial roles of Rab1A/IL-4Rα expression in predicting the prognosis of GC patients. Therefore, Rab1A/IL-4Rα is vital in GC, providing a novel perspective on targeted GC therapy.

show abstract

Section: Discussionmentioning

confidence: 92%

“…Recent studies indicated Rab1A, an oncogene, is aberrantly elevated in various cancers. Furthermore, Rab1A overexpression led to poor prognoses, including lung cancer 16 , liver cancer 17 , and colorectal cancer 30 . A previous study reported that Rab1A and IL4Ra expression is highly associated with lung cancer tissues 25 .…”

Section: Discussionmentioning

confidence: 99%

Prognosis value and positive association of Rab1A/IL4Rα aberrant expression in gastric cancer

Cheng

Jiang

et al. 2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous study has reported that Rab1A overexpression led to a poor prognosis in CRC 9,30,31 , GC 32 and intrahepatic cholangiocarcinoma 19 . Our results suggest that Rab1A positive group had a worse prognosis compared with the negative group in GC patient.…”

Section: Discussionmentioning

confidence: 93%

“…Furthermore, Rab1A overexpression led to poor prognosis, such as lung cancer 16 , liver cancer 17 , colorectal cancer 30 . Previous study reported that the expression of Rab1A and IL4Ra is highly correlated in lung cancer tissues 25 .…”

Section: Discussionmentioning

confidence: 99%

Prognosis value and positive association of Rab1A/IL4Rα aberrant expression in gastric cancer

Cheng

Jiang

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Gastric cancer (GC) is the most common gastrointestinal cancer with the leading causes of cancer-related death worldwide. Many GC patients are diagnosed at the advanced stage, the five-year survival rate is unsatisfactory. Rab1A expression was significantly correlated with IL4Rα expression in non-small cell lung cancer. However, the potential correlation of Rab1A and IL4Rα in both expression and prognosis remain largely unknown in gastric cancer. In this study, Rab1A/IL-4Rα was obviously elevated in GC tissues compared with the para-cancerous tissues and Rab1A/IL-4Rα overexpression led to poor prognosis in GC patients. Rab1A expression was remarkably associated with the expression of IL-4Rα in GC tissues by IHC analysis. In addition, the mRNA expression of Rab1A was closely related with the IL-4Rα mRNA expression by qPCR in GC tissue. Furthermore, the Kaplan-Meier analysis indicated that the group with both negative of Rab1A and IL-4Rα expression had longer five-year survival rates compared with the other group. Besides, the group with both positive of Rab1A and IL-4Rα expression had a worse prognosis compared with the other group. Finally, the nomograms predicting 3 and 5-year overall survival revealed that Rab1A/IL-4Rα expression played crucial roles in predicting the prognosis of GC patients. Therefore, Rab1A/IL-4Rα may played a vital role in GC, which may provide a new visual field on the targeted therapy of GC.

show abstract

“…Overall, RAB1A emerges as a promising candidate for targeted intervention in colorectal cancer, with its interaction with FoxM1 warranting deeper exploration. (43),(44),(45)…”

Section: Introductionmentioning

confidence: 99%

AI-Enhanced RAIN Protocol: A Systematic Approach to Optimize Drug Combinations for Rectal Neoplasm Treatment

Dashti,

Kiaei,

Boush

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundRectal cancers, or rectal neoplasms, are tumors that develop from the lining of the rectum, the concluding part of the large intestine ending at the anus. These tumors often start as benign polyps and may evolve into malignancies over several years. The causes of rectal cancer are diverse, with genetic mutations being a key factor. These mutations lead to uncontrolled cell growth, resulting in tumors that can spread and damage healthy tissue. Age, genetic predisposition, diet, and hereditary conditions are among the risk factors. Treating rectal cancer is critical to prevent severe health issues and death. Untreated, it can cause intestinal blockage, metastasis, and deteriorate the patient’s quality of life. Effective treatment hinges on finding the right drug combinations to improve therapeutic outcomes. Given the intricacies of cancer biology, treatments often combine surgery, chemotherapy, and radiation, with drugs chosen to target different tumor growth mechanisms, aiming to reduce the tumor and limit side effects. The continuous advancement in cancer treatments highlights the need for ongoing research to discover new drug combinations, offering patients improved recovery prospects and a better quality of life. This background encapsulates a detailed yet succinct understanding of rectal neoplasms, their origins, the urgency of treatment, and the quest for effective drug therapies, paving the way for discussions on treatment advancements and patient care impacts.MethodThis study employed the RAIN protocol, comprising three steps: firstly, utilizing the GraphSAGE model to propose drug combinations for rectal neoplasm treatment Each node in the graph model is a drug or a human gene/protein that acts as potential target for the disease, and the edges are P-values between them; secondly, conducting a systematic review across various databases including Web of Science, Google Scholar, Scopus, Science Direct, PubMed, and Embase, with NLP investigation; and thirdly, employing a meta-analysis network to assess the efficacy of drugs and genes in relation to each other. All implementations was conducted using Python software.ResultThe study evaluated the efficacy of Oxaliplatin, Leucovorin, and Capecitabine in treating Rectal Neoplasms, confirming their effectiveness through a review of 30 studies. The p-values for individual drugs were 0.019, 0.019, and 0.016 respectively, while the combined use of all three yielded a p-value of 0.016.ConclusionGiven the significance of rectal neoplasms, policymakers are urged to prioritize the healthcare needs of affected individuals. Utilizing artificial intelligence within the RAIN protocol can offer valuable insights for tailoring effective drug combinations to better address the treatment and management of rectal neoplasms patients.Abstract FigureHighlightsRectal cancers, evolving from benign polyps to malignancies, underscore the critical need for timely and effective treatment to prevent severe health complications.Genetic mutations, a pivotal factor in rectal cancer, trigger uncontrolled cell growth and necessitate targeted drug therapies to combat tumor spread.The RAIN protocol, leveraging the GraphSAGE model and systematic reviews, offers a novel approach to identify potent drug combinations for rectal neoplasm treatment.The study’s findings advocate for policy intervention to ensure that healthcare systems adequately support individuals battling rectal neoplasms, with AI-driven protocols enhancing patient care.

show abstract

Clinical value and potential association of Rab1A and FoxM1 aberrant expression in colorectal cancer

Cited by 4 publications

References 29 publications

Prognosis value and positive association of Rab1A/IL4Rα aberrant expression in gastric cancer

Prognosis value and positive association of Rab1A/IL4Rα aberrant expression in gastric cancer

Prognosis value and positive association of Rab1A/IL4Rα aberrant expression in gastric cancer

AI-Enhanced RAIN Protocol: A Systematic Approach to Optimize Drug Combinations for Rectal Neoplasm Treatment

Contact Info

Product

Resources

About